citalopram has been researched along with Inflammation in 16 studies
Citalopram: A furancarbonitrile that is one of the serotonin uptake inhibitors used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from TARDIVE DYSKINESIA in preference to tricyclic antidepressants, which aggravate dyskinesia.
citalopram : A racemate comprising equimolar amounts of (R)-citalopram and its enantiomer, escitalopram. It is used as an antidepressant, although only escitalopram is active.
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile : A nitrile that is 1,3-dihydro-2-benzofuran-5-carbonitrile in which one of the hydrogens at position 1 is replaced by a p-fluorophenyl group, while the other is replaced by a 3-(dimethylamino)propyl group.
Inflammation: A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.
| Excerpt | Relevance | Reference |
|---|---|---|
| "There was no major effect of inflammation on the metabolism of citalopram and venlafaxine." | 7.81 | Retrospective pilot study for analysis of antidepressant serum concentrations of citalopram and venlafaxine during inflammation. ( Falter, T; Hefner, G; Hiemke, C; Shams, ME; Unterecker, S, 2015) |
| " We investigated the antiallodynic and antihyperalgesic effects of intrathecally administered morphine, citalopram, paroxetine, and combinations thereof, in a rat model in which peripheral inflammation was induced by complete Freund's adjuvant (CFA)." | 7.78 | Interaction of morphine and selective serotonin receptor inhibitors in rats experiencing inflammatory pain. ( Jun, IG; Kim, SH; Lee, BS; Park, JY, 2012) |
| "Depression is a common affective disorder or mood disorder, which seriously affects people's physical and mental health and the quality of life." | 6.87 | Analysis of curative effect of fluoxetine and escitalopram in the depression treatment based on clinical observation. ( Xiaoling, Z; Yingdong, L; Yunping, H, 2018) |
| " The authors tested the hypothesis that C-reactive protein (CRP), a commonly available marker of systemic inflammation, predicts differential response to escitalopram (a serotonin reuptake inhibitor) and nortriptyline (a norepinephrine reuptake inhibitor)." | 5.19 | An inflammatory biomarker as a differential predictor of outcome of depression treatment with escitalopram and nortriptyline. ( Dernovsek, MZ; Dew, T; Farmer, A; Hauser, J; Henigsberg, N; Maier, W; McGuffin, P; Mors, O; Souery, D; Tansey, KE; Uher, R, 2014) |
| "There was no major effect of inflammation on the metabolism of citalopram and venlafaxine." | 3.81 | Retrospective pilot study for analysis of antidepressant serum concentrations of citalopram and venlafaxine during inflammation. ( Falter, T; Hefner, G; Hiemke, C; Shams, ME; Unterecker, S, 2015) |
| " We investigated the antiallodynic and antihyperalgesic effects of intrathecally administered morphine, citalopram, paroxetine, and combinations thereof, in a rat model in which peripheral inflammation was induced by complete Freund's adjuvant (CFA)." | 3.78 | Interaction of morphine and selective serotonin receptor inhibitors in rats experiencing inflammatory pain. ( Jun, IG; Kim, SH; Lee, BS; Park, JY, 2012) |
| "Depression is a common affective disorder or mood disorder, which seriously affects people's physical and mental health and the quality of life." | 2.87 | Analysis of curative effect of fluoxetine and escitalopram in the depression treatment based on clinical observation. ( Xiaoling, Z; Yingdong, L; Yunping, H, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (12.50) | 29.6817 |
| 2010's | 13 (81.25) | 24.3611 |
| 2020's | 1 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| Kofod, J | 1 |
| Elfving, B | 1 |
| Nielsen, EH | 1 |
| Mors, O | 3 |
| Köhler-Forsberg, O | 1 |
| Jha, MK | 1 |
| Minhajuddin, A | 1 |
| Gadad, BS | 1 |
| Greer, TL | 1 |
| Mayes, TL | 1 |
| Trivedi, MH | 1 |
| Xiaoling, Z | 1 |
| Yunping, H | 1 |
| Yingdong, L | 1 |
| Aguilar-Valles, A | 1 |
| Haji, N | 1 |
| De Gregorio, D | 1 |
| Matta-Camacho, E | 1 |
| Eslamizade, MJ | 1 |
| Popic, J | 1 |
| Sharma, V | 1 |
| Cao, R | 1 |
| Rummel, C | 1 |
| Tanti, A | 1 |
| Wiebe, S | 1 |
| Nuñez, N | 1 |
| Comai, S | 1 |
| Nadon, R | 1 |
| Luheshi, G | 1 |
| Mechawar, N | 1 |
| Turecki, G | 1 |
| Lacaille, JC | 1 |
| Gobbi, G | 1 |
| Sonenberg, N | 1 |
| Zwicker, A | 1 |
| Fabbri, C | 1 |
| Rietschel, M | 1 |
| Hauser, J | 2 |
| Maier, W | 2 |
| Zobel, A | 1 |
| Farmer, A | 2 |
| Aitchison, KJ | 1 |
| McGuffin, P | 3 |
| Lewis, CM | 1 |
| Uher, R | 4 |
| Zhong, Q | 1 |
| Yu, H | 1 |
| Huang, C | 1 |
| Zhong, J | 1 |
| Wang, H | 1 |
| Xu, J | 1 |
| Cheng, Y | 1 |
| do Prado-Lima, PAS | 1 |
| Onsten, GA | 1 |
| de Oliveira, GN | 1 |
| Brito, GC | 1 |
| Ghilardi, IM | 1 |
| de Souza, EV | 1 |
| Dos Santos, PG | 1 |
| Salamoni, SD | 1 |
| Machado, DC | 1 |
| Duarte, MMF | 1 |
| Barbisan, F | 1 |
| da Cruz, IBM | 1 |
| Costa-Ferro, ZSM | 1 |
| daCosta, JC | 1 |
| Powell, TR | 1 |
| Tansey, KE | 2 |
| Breen, G | 1 |
| Farmer, AE | 1 |
| Craig, IW | 1 |
| D'Souza, UM | 1 |
| Schalkwyk, LC | 1 |
| Dew, T | 1 |
| Dernovsek, MZ | 1 |
| Henigsberg, N | 1 |
| Souery, D | 1 |
| Kunte, H | 1 |
| Rentzsch, J | 1 |
| Kronenberg, G | 1 |
| Hefner, G | 1 |
| Shams, ME | 1 |
| Unterecker, S | 1 |
| Falter, T | 1 |
| Hiemke, C | 1 |
| Hannestad, J | 1 |
| Lee, BS | 1 |
| Jun, IG | 1 |
| Kim, SH | 1 |
| Park, JY | 1 |
| Leo, R | 1 |
| Di Lorenzo, G | 1 |
| Tesauro, M | 1 |
| Razzini, C | 1 |
| Forleo, GB | 1 |
| Chiricolo, G | 1 |
| Cola, C | 1 |
| Zanasi, M | 1 |
| Troisi, A | 1 |
| Siracusano, A | 1 |
| Lauro, R | 1 |
| Romeo, F | 1 |
| Eller, T | 1 |
| Vasar, V | 1 |
| Shlik, J | 1 |
| Maron, E | 1 |
6 trials available for citalopram and Inflammation
| Article | Year |
|---|---|
Depression and inflammation: Correlation between changes in inflammatory markers with antidepressant response and long-term prognosis.
Topics: Adult; Antidepressive Agents; Biomarkers; Citalopram; Depression; Depressive Disorder, Major; Female | 2022 |
Analysis of curative effect of fluoxetine and escitalopram in the depression treatment based on clinical observation.
Topics: Adult; Antidepressive Agents, Second-Generation; Citalopram; Cytokines; Depression; Female; Fluoxeti | 2018 |
Genetic disposition to inflammation and response to antidepressants in major depressive disorder.
Topics: Adrenergic Uptake Inhibitors; Adult; C-Reactive Protein; Citalopram; Depressive Disorder, Major; Fem | 2018 |
An inflammatory biomarker as a differential predictor of outcome of depression treatment with escitalopram and nortriptyline.
Topics: Academic Medical Centers; Adult; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tr | 2014 |
Association between enhanced soluble CD40 ligand and proinflammatory and prothrombotic states in major depressive disorder: pilot observations on the effects of selective serotonin reuptake inhibitor therapy.
Topics: Adult; Biomarkers; CD40 Ligand; Citalopram; Depressive Disorder, Major; Factor VIIa; Female; Humans; | 2006 |
Pro-inflammatory cytokines and treatment response to escitalopram in major depressive disorder.
Topics: Adult; Age Factors; Citalopram; Cytokines; Depressive Disorder, Major; Female; Humans; Inflammation; | 2008 |
10 other studies available for citalopram and Inflammation
| Article | Year |
|---|---|
Interleukin 17 selectively predicts better outcomes with bupropion-SSRI combination: Novel T cell biomarker for antidepressant medication selection.
Topics: Adult; Antidepressive Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricy | 2017 |
Translational control of depression-like behavior via phosphorylation of eukaryotic translation initiation factor 4E.
Topics: Animals; Antidepressive Agents; Anxiety; Behavior, Animal; Benzofurans; Citalopram; Depression; Depr | 2018 |
FCPR16, a novel phosphodiesterase 4 inhibitor, produces an antidepressant-like effect in mice exposed to chronic unpredictable mild stress.
Topics: Animals; Antidepressive Agents; Benzamides; Cerebral Cortex; Chronic Disease; Citalopram; Cyclic AMP | 2019 |
The antidepressant effect of bone marrow mononuclear cell transplantation in chronic stress.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Bone Marrow Transplantation; Chronic Disease; Cita | 2019 |
ATP-binding cassette sub-family F member 1 (ABCF1) is identified as a putative therapeutic target of escitalopram in the inflammatory cytokine pathway.
Topics: Adult; Aged; Antidepressive Agents; ATP-Binding Cassette Transporters; Citalopram; Cytokines; Depres | 2013 |
Response to Kunte et al.
Topics: Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; C-Reactive Protein; Cita | 2015 |
A new role for nortriptyline in depression associated with vascular disease?
Topics: Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; C-Reactive Protein; Cita | 2015 |
Retrospective pilot study for analysis of antidepressant serum concentrations of citalopram and venlafaxine during inflammation.
Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents; C-Reactive Protein; Citalopram; Female; Human | 2015 |
Comment on "Paroxetine prevents loss of nigrostriatal dopaminergic neurons by inhibiting brain inflammation and oxidative stress in an experimental model of Parkinson's disease".
Topics: Animals; Anti-Inflammatory Agents; Brain; Citalopram; Encephalitis; Humans; Inflammation; Lipopolysa | 2010 |
Interaction of morphine and selective serotonin receptor inhibitors in rats experiencing inflammatory pain.
Topics: Analgesics, Opioid; Animals; Behavior, Animal; Citalopram; Disease Models, Animal; Hyperalgesia; Inf | 2012 |